![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Omexa will be responsible for developing an anti-cancer biosimilar product from the initial stages of development through clinical trials, leading to its eventual commercial launch.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Omexa Formulary
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 28, 2024